Cross-reactivity testing is one of the most under-resourced parts of IVD performance evaluation — until a Notified Body review flags missing data two weeks before your submission deadline. This post gives you a practical checklist of disease state serum panels commonly required for IVDR performance evaluation, organised by assay type, so you can plan your sourcing timeline correctly.
Why cross-reactivity testing matters for IVDR
An IVD that correctly identifies positive and negative samples from healthy donors or confirmed-positive patients does not automatically perform correctly in a clinical population. Patients are rarely single-disease — they have co-morbidities, concurrent infections, elevated inflammatory markers, unusual antibody profiles, and metabolic disorders that can interact with the assay chemistry to produce false positives or altered quantitative results.
IVDR performance evaluation under EU Regulation 2017/746 requires demonstration that the device performs as intended in the full range of conditions it will encounter in the intended-use population. For a thyroid assay used in a general clinical laboratory, that population includes patients with autoimmune conditions, lipid disorders, and concurrent infections — all of which can interfere with immunoassays.
The general interference panel — start here
Before building your disease-specific cross-reactivity panel, every IVD performance evaluation should include a general interference panel covering the most common sources of non-specific interference in immunoassays:
| Interferent | Mechanismus | Typical level to test |
|---|---|---|
| Rheumatoid Factor (RF) | IgM anti-IgG — bridges murine capture and detection antibodies in sandwich assays | High positive — >500 IU/mL |
| Antinuclear Antibodies (ANA) | Non-specific antibody binding to assay components | ANA positive, titre >1:160 |
| HAMA (Human Anti-Mouse Antibodies) | Bridges murine antibodies in sandwich format — false positive signal | High positive >100 ng/mL |
| Lipemia | Optical interference, protein binding displacement | Triglycerides >1,000 mg/dL |
| Icterus (bilirubin) | Optical interference at wavelengths used for detection | Bilirubin >20 mg/dL |
| Haemolysis | Haemoglobin optical interference, released intracellular enzymes | Haemoglobin >500 mg/dL |
| Biotin (Vitamin B7) | Competes with biotinylated assay components in streptavidin-biotin based assays | >1,000 ng/mL — seen in supplement users |
| Polyclonal hypergammaglobulinaemia | Elevated total IgG causes non-specific background | Total IgG >30 g/L |
Cross-reactivity checklist by assay type
Infectious disease assays (HIV, HBV, HCV)
Cross-reactivity testing for infectious disease assays is largely defined by the CTS 2009/108/EC. Beyond the general interference panel, include:
- Co-infections: HIV-positive donors for HBV and HCV assays (and vice versa)
- Other hepatitis viruses: HAV, HEV, HDV antibody-positive donors
- Herpes virus group: CMV, EBV, HSV-1/2, VZV antibody-positive
- Respiratory pathogens: Influenza A/B, Mycoplasma pneumoniae, Chlamydia pneumoniae
- Sexually transmitted: Syphilis (Treponema pallidum), Chlamydia trachomatis, HSV-2
- Tropical: Malaria (Plasmodium antibody and antigen), Toxoplasma gondii, Leishmania
- Vaccinated donors: Hepatitis B vaccine, MMR, influenza
- Pregnant donors: 100–200 pregnant women (1st, 2nd, 3rd trimester)
Thyroid assays (TSH, fT4, fT3, anti-TPO, TRAb)
Thyroid assays are among the most interference-prone immunoassays in clinical chemistry. Specific cross-reactivity concerns:
- Heterophile antibodies and HAMA — very common source of TSH false positives
- Anti-TPO positive donors — for TSH and fT4 assays where antibody binding affects free hormone measurement
- TRAb positive donors — for TSH receptor antibody interference in TSH assays
- Anti-Tg positive — for thyroglobulin assay interference testing
- Graves’ Disease and Hashimoto’s patients — confirmed clinical diagnosis
- Pregnancy serum — TSH suppression in first trimester is physiological; assay must distinguish from pathological suppression
- Biotin interference — particularly important for thyroid assays using streptavidin-biotin platforms (TSH, fT4 on Roche Elecsys)
Autoimmune assays (ANA, anti-CCP, RF, dsDNA)
- Co-existing autoimmune conditions: SLE, Rheumatoid Arthritis, Sjögren’s Syndrome, Myasthenia gravis, Primary Biliary Cholangitis — overlap syndromes are common
- Infectious triggers: Post-infectious ANA positivity — EBV, CMV, HCV can transiently induce ANA
- Age and gender: Elderly female donors have higher baseline ANA positivity rates
- Medications: Some drugs (hydralazine, procainamide, isoniazid) induce drug-related lupus with ANA positivity — medication history should be documented in donor records
Cardiac markers (troponin, BNP, NT-proBNP, CK-MB)
- HAMA — the most important interferent for troponin assays using murine antibodies
- RF — high RF can bridge murine antibodies producing false positive troponin
- Renal failure serum — elevated creatinine (troponin is renally cleared — elevated in CKD without cardiac damage)
- Skeletal muscle injury: elevated CK-MM and myoglobin can interfere with CK-MB assays
- Haemolysis: particularly important for troponin I assays where released haemoglobin interferes
Allergy assays (total IgE, specific IgE)
- Polyclonal hypergammaglobulinaemia — elevated total immunoglobulins can produce false elevated total IgE
- Parasitic infection: Ascaris, Toxocara, Schistosoma infection causes polyclonal IgE elevation mimicking allergy
- Atopic dermatitis: very high total IgE (>5,000 IU/mL) — assay linearity and hook effect testing
- Concurrent autoimmune: IgE deficiency occurs in some autoimmune conditions
Planning your cross-reactivity sourcing timeline
The most common mistake is treating cross-reactivity panel sourcing as an afterthought — something to arrange after the main sensitivity/specificity study is designed. In practice, some materials have long lead times:
- Standard panels (RF, ANA, lipemic, icteric, haemolytic): typically available from stock — 1–2 weeks
- Specific infectious disease positives (malaria, HTLV, leishmania): rare — 4–8 weeks lead time
- HAMA high positive: uncommon — 2–4 weeks
- Drug-induced conditions: requires medication documentation — 4–8 weeks
- Pregnancy cohorts: requires collection coordination — 4–8 weeks for trimester-specific
Build your cross-reactivity panel sourcing into your study protocol timeline at the same time as your sensitivity/specificity panels — not after.
Practical next steps
SeamlessBio supplies disease state serum and plasma for IVDR cross-reactivity testing across all major diagnostic areas — autoimmune, infectious, thyroid, allergy, diabetes, oncology, and drugs of abuse. Materials are native human biomaterial with confirmed diagnostic results, full donor documentation, and IVDR documentation on request.
English 
Deutsch